Press Release

Innovative Project to develop a Wearable Device for Non-invasive Biomarker Monitoring Launched with European Innovation Council Funding.

Berlin, GermanyQUANTUNE TECHNOLOGIES GmbH is excited to announce the initiation of the MiWear project, a pioneering effort supported by the European Innovation Council (EIC) with a grant agreement ID 101115476. Funded fully by the EU with an investment of €3,991,297, MiWear started on January 1, 2024, aiming to transform the management of metabolic syndrome (MetS) and its associated conditions through innovative monitoring technologies.

About MiWear

MiWear is designed to transition healthcare from a traditional reactive model to a proactive stance. It utilizes a groundbreaking mid-infrared wearable device for the non-invasive, painless monitoring of biomarkers directly in the interstitial fluid. This leap is made possible by miniaturizing Mid-Infrared spectrometry technology, enabling on-the-go monitoring of critical biomarkers like uric acid, albumin, and ketone bodies, thus improving the precision of MetS diagnostics and reducing the likelihood of diagnostic errors.

Objective and Impact

Addressing the critical need for early detection and ongoing monitoring of MetS — a significant health and economic burden across Europe — MiWear is poised to mitigate risks associated with MetS such as arteriosclerosis, heart attacks, and strokes through innovative healthcare technology.

Consortium and Collaboration

Coordinated by QUANTUNE TECHNOLOGIES GmbH, the MiWear project synergises a consortium of leading experts across various fields, including biomarkers, optical spectroscopy, and laser physics. This collaboration emphasizes the project’s dedication to nurturing young researchers and broadening the impact and outreach of its innovations.

Consortium partners: Joanneum Research Forschungsgesellschaft MBH (Austria); VTT OY (Finland); Artificial Intelligence Experts SRL (Romania); FRESCI by SCIENCE&STRATEGY SL (Spain); and Stichting Radboud Universitair Centrum (Netherlands).

Future Prospects

With a project timeline extending to December 31, 2026, MiWear aspires to redefine standards in MetS management, facilitating early detection and personalized healthcare approaches. Its success is anticipated to enhance patient convenience by offering a non-invasive monitoring alternative, alongside reducing the economic strain of late-stage MetS treatment and complications.

For more detailed information and future updates on the MiWear project, please contact:


A leader in optical spectroscopy and laser physics, QUANTUNE TECHNOLOGIES GmbH is committed to advancing healthcare through innovative technologies aimed at enhancing patient care and reducing treatment costs.

About the European Innovation Council (EIC)

The EIC fosters groundbreaking projects with the potential to create new markets and achieve international scale. As an integral part of the EU’s Horizon Europe program, it offers comprehensive support including funding, advisory services, and networking opportunities to transform scientific discoveries into market-ready innovations.